1. INTRODUCTION 1.1 MARKET DEFINITION 2. RESEARCH METHODOLOGY 3. EXECUTIVE SUMMARY 4. KEY INFERENCES 5. MARKET OVERVIEW 5.1 CURRENT MARKET SCENARIO 5.2 PORTERS FIVE FORCES 5.2.1 BARGAINING POWER OF SUPPLIERS 5.2.2 BARGAINING POWER OF CONSUMERS 5.2.3 THREATS OF NEW ENTRANTS 5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES 5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY 6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC) 6.1 MARKET DRIVERS 6.1.1 INCREASING EMPHASIS ON EARLY DISEASE DETECTION AND PREVENTION 6.1.2 GROWING DEMAND FOR THE PERSONALIZED MEDICINE 6.1.3 INCREASING APPLICATION OF GENETIC TESTING IN ONCOLOGY 6.2 MARKET RESTRAINTS 6.2.1 HIGH COSTS OF GENETIC TESTING 6.2.2 SOCIAL AND ETHICAL IMPLICATIONS OF GENETIC TESTING 6.2.3 NON-INCLUSION OF REIMBURSEMENT POLICIES 6.3 OPPORTUNITIES 6.4 KEY CHALLENGES 7. MARKET SEGMENTATION 7.1 SEGMENTATION BY TYPE 7.1.1 CARRIER TESTING 7.1.2 DIAGNOSTIC TESTING 7.1.3 NEWBORN SCREENING 7.1.4 PREDICTIVE AND PRESYMPTOMATIC TESTING 7.1.5 PRENATAL TESTING 7.2 SEGEMENTATION BY GEOGRAPHY 7.2.1 NORTH AMERICA 7.2.1.1 UNITED STATES 7.2.1.2 CANADA 7.2.1.3 MEXICO 8. COMPETITIVE LANDSCAPE 8.1 MERGERS AND ACQUISITION ANALYSIS 8.2 AGREEMENTS, COLLABORATIONS & PARTNERSHIPS 8.3 NEW PRODUCTS LAUNCHES 9. COMPANY PROFILES 9.1 23ANDME INC. 9.2 ABBOTT MOLECULAR INC 9.3 ARIOSA DIAGNOSTICS INC 9.4 BIOCARTIS SA 9.5 CEPHEID 9.6 ILLUMINA INC 9.7 LUMINEX CORPORATION 9.8 SEQUENOM INC 9.9 MYRIAD GENETICS 9.10 TRANSGENOMIC INC. 10. FUTURE OUTLOOK OF THE MARKET

23ANDME INC., ABBOTT MOLECULAR INC., ARIOSA DIAGNOSTICS INC (ROCHE), BIOCARTIS SA, CEPHEID, ILLUMINA, INC, LUMINEX CORPORATION, SEQUENOM INC., MYRIAD GENETICS, TRANSGENOMIC, INC.